Cargando…
Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high pe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357729/ https://www.ncbi.nlm.nih.gov/pubmed/33881757 http://dx.doi.org/10.1007/s42000-021-00292-4 |
_version_ | 1783737191868923904 |
---|---|
author | Timmons, J. G. Manners, R. Bailey, M. McDougall, C. |
author_facet | Timmons, J. G. Manners, R. Bailey, M. McDougall, C. |
author_sort | Timmons, J. G. |
collection | PubMed |
description | Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high peri-operative risk. We present an elderly patient with mild hypercalcemia secondary to primary hyperparathyroidism. The clinical decision was initially to watch and wait. The patient subsequently developed cognitive impairment and was diagnosed with mixed Alzheimer’s disease/vascular dementia. She became dependent for all care and housebound. A therapeutic trial of cinacalcet was commenced following a further acute rise in serum calcium. Significant reversal of her functional and cognitive deficit occurred. She was no longer fully dependent. Mini mental state examination (MMSE) improved from 8/30 to 21/30. In vulnerable neural systems, even mild elevation in serum calcium may have a profound effect on cognition and function. We propose a therapeutic trial of cinacalcet in such patients. |
format | Online Article Text |
id | pubmed-8357729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83577292021-08-30 Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism Timmons, J. G. Manners, R. Bailey, M. McDougall, C. Hormones (Athens) Teaching Case Presentations Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high peri-operative risk. We present an elderly patient with mild hypercalcemia secondary to primary hyperparathyroidism. The clinical decision was initially to watch and wait. The patient subsequently developed cognitive impairment and was diagnosed with mixed Alzheimer’s disease/vascular dementia. She became dependent for all care and housebound. A therapeutic trial of cinacalcet was commenced following a further acute rise in serum calcium. Significant reversal of her functional and cognitive deficit occurred. She was no longer fully dependent. Mini mental state examination (MMSE) improved from 8/30 to 21/30. In vulnerable neural systems, even mild elevation in serum calcium may have a profound effect on cognition and function. We propose a therapeutic trial of cinacalcet in such patients. Springer International Publishing 2021-04-21 2021 /pmc/articles/PMC8357729/ /pubmed/33881757 http://dx.doi.org/10.1007/s42000-021-00292-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Teaching Case Presentations Timmons, J. G. Manners, R. Bailey, M. McDougall, C. Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title | Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title_full | Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title_fullStr | Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title_full_unstemmed | Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title_short | Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
title_sort | cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism |
topic | Teaching Case Presentations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357729/ https://www.ncbi.nlm.nih.gov/pubmed/33881757 http://dx.doi.org/10.1007/s42000-021-00292-4 |
work_keys_str_mv | AT timmonsjg cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism AT mannersr cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism AT baileym cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism AT mcdougallc cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism |